Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4115173 | 0.83 | MEN1 (0.80) | MEN1KMT2ALMNAPOLBSMN1; SMN2 | |
| SCHEMBL4125608 | 0.81 | MEN1 (0.61) | MEN1KMT2ALMNAPOLBSMN1; SMN2 | |
| SCHEMBL4119653 | 0.75 | MEN1 (0.54) | MEN1KMT2ALMNAPOLBSMN1; SMN2 | |
| SCHEMBL4115503 | 0.75 | KMT2A (0.54) | MEN1KMT2ALMNAPOLBSMN1; SMN2 | |
| SCHEMBL4120282 | 0.72 | MEN1 (0.60) | MEN1KMT2ALMNAPOLBALDH1A1 | |
| SCHEMBL11070209 | 0.70 | MEN1 (0.47) | MEN1KMT2ALMNAPOLBSMN1; SMN2 | |
| SCHEMBL10942583 | 0.69 | MEN1 (0.68) | MEN1KMT2ALMNAPOLBSMN1; SMN2 | |
| SCHEMBL4118978 | 0.69 | GAA (0.59) | MEN1KMT2ALMNASMN1; SMN2GAA | |
| SCHEMBL4113680 | 0.69 | MCHR1 (0.54) | MEN1KMT2ALMNAPOLBALDH1A1 | |
| SCHEMBL4114264 | 0.69 | LMNA (0.79) | MEN1KMT2ALMNAPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | ACTIVE BIOTECH AB (SE) | 2009-05-07 | — | — | US | disclosed |
| CN-1917873-A | Diurea derivatives | ACTIVE BIOTECH AB (SE) | 2007-02-21 | — | — | CN | disclosed |
| EP-1711175-A1 | DIUREA DERIVATIVES | Active Biotech AB (SE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005074919-A1 | DIUREA DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | IL2, CASP2, MAVS | MEN1 4167/4885KMT2A 2720/4885LMNA 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.